v3.26.1
Condensed Interim Consolidated Statements of Financial Position (Unaudited) - CAD ($)
Jun. 30, 2026
Dec. 31, 2025
Current assets    
Cash $ 388,724 $ 4,665,392
Trade and other receivables 4,226,093 3,798,016
Scientific research and experimental development tax credits receivable 61,181 49,200
Accrued revenues (Note 3) 2,726,983 2,724,647
Inventories (Note 4) 6,393,232 6,389,739
Prepaid expenses 75,791 59,348
Security deposits and deposits on purchase of goods 1,370,345 1,313,447
Loan receivable (Note 5) 77,347 77,347
Current assets 15,319,696 19,077,136
Non-current assets    
Property, plant and equipment (Note 6) 3,694,283 3,059,201
Intangible assets (Note 7) 7,372,530 7,472,426
Right-of-use assets (Note 8) 451,704 389,407
Non-current assets 11,518,516 10,921,034
Total assets 26,838,213 29,998,169
Current liabilities    
Trade and other payables 10,694,488 10,456,567
Customer advances (Note 9) 1,215,262 1,154,191
Loans payable (Note 10) 8,598,931 7,297,100
Convertible debentures (Note 12A) 2,645,502 2,645,502
Convertible debentures and derivative liability (Note 12B) 2,966,430 2,432,637
Current portion of lease liabilities (Note 11) 35,000 92,580
Current liabilities 26,155,613 24,078,577
Non-current liabilities    
Lease Liabilities (Note 11) 462,869 323,206
Total liabilities 26,618,483 24,401,783
Shareholders’ equity (Deficiency)    
Share capital (Note 13) 86,654,171 86,606,375
Warrants (Note 14) 6,470,740 6,465,936
Contributed surplus (Note 15) 7,559,538 7,559,538
Foreign exchange in translation of foreign operations (1,605,120) (801,802)
Accumulated deficit (98,859,599) (94,233,661)
Total shareholders’ equity (deficiency) 219,730 5,596,386
Total liabilities and shareholders’ equity (deficiency) $ 26,838,213 $ 29,998,169